Printer Friendly

CEL-SCI ANNOUNCES APPOINTMENT OF CONSULTANT FOR TECHNICAL, CLINICAL AFFAIRS, ENCOURAGING DETAILS FROM FLORIDA CANCER TRIALS

 CEL-SCI ANNOUNCES APPOINTMENT OF CONSULTANT FOR TECHNICAL,


CLINICAL AFFAIRS, ENCOURAGING DETAILS FROM FLORIDA CANCER TRIALS
 ALEXANDRIA, Va., May 1 /PRNewswire/ -- CEL-SCI Corp. (NASDAQ: CELI) has appointed Dr. Michael Chirigos as consultant for technical and clinical affairs. Chirigos has headed the Virus and Disease Modification Section, National Institutes of Health (N.I.H.), National Cancer Institute (N.C.I.) from 1966-1981 and the Immuno Pharmacology Section, N.I.H., N.C.I., Biological Response Modifier Program (B.R.M.P.) until 1985. From 1986 until 1991 he was deputy chief of science, U.S. Army Medical Research Institute of Infectious Diseases. He is the holder of national and international awards. Chirigos is also a member of different societies such as the American Association for Cancer Research and the Biological Response Modifiers Society. He has also served as chairman of the National Research Council Post-Doctoral Fellowship Program and is a member of several other scientific committees.
 Results of the ongoing clinical trial using the company's proprietary BC-IL technology were presented today by John Hadden, M.D., at the Second International Symposium on Combination Therapies in Sicily. Hadden is a co-investigator of this trial and the director of immunopharmacology in the Department of Internal Medicine of the University of South Florida Medical School.
 The first three patients treated with the company's BC-IL product in connection with the head and neck cancer trial being conducted at the H. Lee Moffitt Cancer Center in cooperation with the University of South Florida Medical School showed remarkable responses. These preliminary results indicate that the treatment provided to these patients, with its low cost, ease of out-patient administration and negligible toxicity, seems superior to existing treatments involving recombinant IL-2, LAK or TIL.
 The first patient in the trial was diagnosed with terminal head and neck cancer in 1991, and as all previous treatments had failed, he was not anticipated to survive longer than three months. Treatment began in summer 1991, and the patient showed a tumor regression of over 80 percent after nine weeks. The treatment was terminated in fall 1991 after the treatment cycles as called for in the protocols filed with the Florida Department of Health and Rehabilitative Services were completed. The patient remained stable with man ag eable residual disease much longer than originally anticipated and died subsequently due to a local complication ("Carotoid blow out").
 The second patient was also diagnosed with terminal cancer in 1991. He was not expected to survive longer than three months as all previous treatments had failed. This patient received his first treatment in summer 1991 and after nine weeks showed a tumor regression of over 90 percent. The second patient also completed the treatment cycles as called for in the protocol. He has been off protocol since then.
 Both the first and the second patient underwent the clinical trial period with stable weight, good performance score and were free of visceral disease.
 The third patient was admitted to the program in late summer 1991. Like the two previously mentioned patients, he showed initial tumor responses within seven days of starting the treatment. He then underwent surgery 13 days after receiving the first treatment and was reported to be disease free in the most recent 1992 update from Hadden.
 The Florida clinical trials are being conducted pursuant to approvals obtained from the University of South Florida Medical School Internal Review Board and granted by the Florida Department of Health and Rehabilitative Services. Hadden is the co-investigator and cooperates in these trials with surgeons at the H. Lee Moffitt Cancer Center. Hadden recently advised the company that due to changes in policies at the University of South Florida, all research and development programs funded by third parties must be formalized through an agreement with the University of South Florida directly. As a result of this, the "1984 agreement" between Hadden and the company, which until April 1992 formed the framework for the cooperation between Hadden and CEL-SCI, can no longer continue to serve this purpose. The company and the University of South Florida are presently negotiating the terms of an agreement relating to future research and development work. It is expected that this agreement, if consummated, will address long term funding for research and development programs at the university.
 -0- 5/1/92
 /CONTACT: Matt Haines of Strategic Growth International, 212-826-9622, or Daryll Strahl, 303-979-5735, both for CEL-SCI/
 (CELI) CO: CEL-SCI Corporation ST: Virginia IN: SU: PER


DC -- DC008 -- 5321 05/01/92 09:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 1, 1992
Words:746
Previous Article:COMDATA ANNOUNCES FIRST QUARTER 1992 RESULTS
Next Article:GENSIA REPORTS 1992 FIRST QUARTER RESULTS


Related Articles
CEL-SCI CORPORATION ANNOUNCES ADDITION OF NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI ANNOUNCES APPOINTMENT OF CONSULTANT FOR TECHNICAL, CLINICAL AFFAIRS, ENCOURAGING DETAILS FROM FLORIDA CANCER TRIALS
CEL-SCI CORPORATION NAMES TWO OUTSIDERS TO ITS BOARD OF DIRECTORS
CEL-SCI NAMES DR. EVAN M. HERSH TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI CORPORATION ANNOUNCES ESTABLISHMENT OF PRODUCTION FACILITY
VTI APPOINTS DR. PREM SARIN VICE PRESIDENT OF RESEARCH AND ANNOUNCES PRELIMINARY DATA FROM HGP-30 SCID MOUSE STUDY
Cel-Sci Corporation Hires New Senior Director of Laboratory and Manufacturing Operations.
CEL-SCI Corporation Announces Full Enrollment of Phase II Clinical Trial in Head & Neck Cancer.
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine.
CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters